好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

B-Cell therapy Shared Medical Appointments (BCSMA) lead to faster time to treatment and less indirect care
Practice, Policy, and Ethics
P16 - Poster Session 16 (8:00 AM-9:00 AM)
1-004
Determine if patients who attend BCSMA start treatment faster and utilize less electronic medical record messages (EMRM).
Acquired CNS demyelination is commonly treated with B cell therapies.  Treatment initiation can be burdensome and delayed as patients seek to understand a complex process. Shared medical appointments are opportunities to support and educate. We designed a novel BCSMA to promote understanding of treatment goals, side effects, insurance clearance, and prior patient experience.  We hypothesized that those patients with more information and support would schedule their infusions on-time, while having less questions for their medical team outside of clinic appointments. 

Patients who were newly prescribed B cell therapies in 2021 were offered a BCSMA to review the treatment initiation process and ask medication-related questions in real-time. We used unpaired t-tests to compare the time to treat (TTT), which is time in days from the medication order to the day of first infusion, between those who attended BCSMA to those who did not, as well as to the TTT of patients who did not have access to BCSMA from 2018 to present. We used Wilcoxon-rank sum analysis to compare the EMRM sent from BCSMA and non-BCSMA participants during the TTT.
The mean TTT when BCSMA was not available was 63.1 days in 2018, 55.2 in 2019, and 52.4 in 2020. The mean TTT as of June 2021 for patients who did not attend BCSMA was similar to years prior at 54.0 days, but decreased to 36.5 for patients who attended BCSMA, p=0.001. The total EMRM from BCMA participants was lower than non-BCMA participants, 3 messages per 10 patients (14 total) vs 7 messages per 10 patients (40 total), p=0.016.
Faster treatment times and reduced EMRM were observed in patients who attended BCSMA. BCSMA are viable options to enhance patient adherence and education. 
Authors/Disclosures
Desiree Chizmadia, NP (Cleveland Clinic)
PRESENTER 		Ms. Chizmadia has received personal compensation for serving as an employee of Genentech. Ms. Chizmadia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech .
Deja Rose, MD Dr. Rose has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Mary R. Rensel, MD, FAAN Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for genentech. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG. Dr. Rensel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Rensel has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG. Dr. Rensel has stock in Brain Fresh LLC . The institution of Dr. Rensel has received research support from NMSS. The institution of Dr. Rensel has received research support from Roche- Genentech . The institution of Dr. Rensel has received research support from Biogen.